antithrombotic activity

TRIA-662 (Nicotinamide Chloromethylate) is a niacin metabolite excreted via the urinary system.

EMD-503982 is an orally active, direct factor Xa (FXa) inhibitor that also exhibits inhibitory activity against factor VIIa, and has potential antithrombotic, anticancer, and neuroprotective effects. EMD-503982 can be used in research on thrombotic diseases.

Trombodipine (PCA-4230) is a platelet aggregation inhibitor with antithrombotic activity and protection against Listeria monocytogenes.

Linotroban(CL-871502) is a potent selective thromboxane (TXA2) receptor antagonist with antithrombotic activity.

Fidexaban (CI1031) is a novel, potent, selective and orally active factor Xa inhibitor that has demonstrated antithrombotic activity in a variety of assays

LY 517717 is an orally active inhibitor of coagulation factor Xa with antithrombotic activity for the study of venous thromboembolism (VTE).

Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable, small-molecule, reversible, and direct antagonist of Factor XIa (FXIa). It exhibits potent inhibitory activity across species, with Ki values of 0.11 nM for human, 0.38 nM for rabbit, and 0.64 nM for dog. By targeting FXIa, Milvexian selectively inhibits the intrinsic pathway of the coagulation cascade. It demonstrates robust antithrombotic efficacy in various in vitro and in vivo models while maintaining a favorable safety profile regarding bleeding risk. It is a critical tool for investigating novel anticoagulant strategies in thrombosis and cardiovascular research.

BMS-986141(UDM-003183) is a selective and potent protease-activated receptor-4 (PAR-4) antagonist with oral activity and an IC50 value of 0.4 nM.BMS-98614 exhibits significant antithrombotic effects.

Iliparcil is an antithrombotic compound with oral activity.

BMS-593214 is an active site-directed factor (F) VIIa inhibitor that exhibits antithrombotic and antihaemostatic properties. It acts as a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of FVIIa-activated substrate FX. Additionally, BMS-593214 effectively prevents electroinduced carotid artery thrombosis (AT) and wire-induced vena cava thrombosis (VT).

Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.

Scutellarin (Breviscapin) is a natural flavonoid isolated from Scutellaria baicalensis that exhibits antioxidant, anti-inflammatory, antithrombotic, neuroprotective, and cardioprotective and neuroprotective activities. Scutellarin demonstrates antiviral activity against HIV-1 IIIB, HIV-1 (74V), and HIV-1 KM018. Scutellarin inhibits the RANKL-mediated MAPK/NF-κB pathway (IC₅₀ = 10 μM) and activates the Nrf2/HO-1 antioxidant pathway (EC₅₀ = 5 μM). Scutellarin can be used in natural product development and basic research on cardiovascular and cerebrovascular diseases.

Viquidil hydrochloride (Quinotoxine hydrochloride) is an isomer of Quinidine. Viquidil hydrochloride is an agent of cerebral vasodilator with antithrombotic activity.

WAY-639228-A has potential antithrombotic and anticoagulant activity for the study of cerebral thrombosis.

Razaxaban hydrochloride is a highly potent, selective and orally active inhibitor of factor Xa(Ki of 0.19 nM),has strongly antithrombotic activity.

RWJ-445167 is a thrombin and factor Xa dual inhibitor(Ki of 4.0 nM and 230 nM, respectively), with potent antithrombotic activity.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

Tecarfarin sodium is a novel orally active non-competitive vitamin K epoxide reductase antagonist. Tecarfarin sodium has the antithrombotic activity.

Tecarfarin (ATI-5923) is an orally active, potent vitamin K epoxide reductase (VKOR) antagonist and cannabinoid-1 receptor inverse agonist with antithrombotic activity, which attenuates abdominal pain and increases intestinal transit in mice.

Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor with antithrombotic activity.

LK-732 is a thrombin inhibitor with antithrombotic activity. It exhibits dose-dependent inhibition in models of hypercoagulability, with an IC50 value of 1.3 mg/kg. LK-732 is used in cardiovascular and cerebrovascular research.

Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. It does not directly inhibit the enzymatic activity of FXIa but specifically binds to the FXI zymogen, allosterically inhibiting the activation process of the FXI zymogen by FXIIa. Factor XI-IN-2 suppresses thrombosis in a rabbit arteriovenous (AV) shunt thrombosis model and can be used in antithrombotic research.

RGH-1875 (GYKI 39521) hydriodide is the hydriodide salt form of RGH-1875, which is an orally active antithrombotic agent. It prevents the reduction of fibrinogen levels and platelet counts induced by endotoxins, reduces levels of fibrin degradation products, and inhibits the enhancement of endotoxin-induced fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 is applicable for research on thrombotic disorders.

RGH-1962 is an orally active antithrombotic agent. It prevents the endotoxin-induced reduction in fibrinogen levels and platelet count, decreases fibrin degradation product levels, and inhibits the enhancement of fibrinolytic activity in an endotoxin-induced disseminated intravascular coagulation model in rabbits. RGH-1962 is applicable for research in thrombotic diseases.